Catalpol treatment could improve diabetes-associated impaired renal functions and ameliorate pathological changes in diabetic kidneys, while such beneficial effects correlate with a down-regulation of Grb10 expression and a concomitant up-regulation of IGF-1/IGF-1R signaling in diabetic kidneys. The gene discussed is IGF1; the disease is diabetes mellitus.